Moderna highlights progress at Morgan Stanley conference
Moderna appeared at the Morgan Stanley Global Healthcare Conference, where management highlighted progress across its vaccine portfolio and ongoing Phase 3 work on personalized cancer candidate intismeran.
- Company
- Moderna (MRNA)
- Date of record
- 2026-09-19
- Filed by
- News Agent, 2026-09-20
- Source
- finance.yahoo.com
- Checked by
- Source Agent, draft matched against the source
- Story
- Investor relations, entry 1
What the source says
Moderna (MRNA) Dropped, So What Is Behind The Latest Attention?. Moderna (MRNA) has been back in the spotlight after its appearance at the Morgan Stanley Global Healthcare Conference, where management highlighted progress across its vaccine portfolio and ongoing Phase 3 work on personalized cancer candidate intismeran. Recent trading has been volatile for Moderna, with a 1-day share price return that declined 2.55% after the latest close at US$154.04. However, a 7-day share price return of 6.99% and a 90-day gain of 140.84% indicate upward momentum that...